{"id":203233,"name":"SANOFI U.S. SERVICES, INC.","slug":"sanofi-us-services-inc","state":"DC","country":"United States of America","description":"Multinational Pharmaceutical Company.","totalSpending":1580000,"filings":28,"yearlySpending":[{"year":2019,"income":140000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"PHA","display":"Pharmacy"},{"code":"TRD","display":"Trade (domestic/foreign)"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"CPT","display":"Copyright/Patent/Trademark"}],"firms":["MARSHALL & POPP, LLC"],"lobbyists":["MONICA POPP","HAZEN MARSHALL"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Natl Economic Council (NEC)","Office of Management & Budget (OMB)","White House Office","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues.","Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues.","Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues.","Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues.","Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues."]}